Hoth Therapeutics Announces Positive Data from HT-VA Study
Hoth Therapeutics announced positive data from its HT-VA study, conducted under its Cooperative Research and Development Agreement, or CRADA, with the U.S. Department of Veterans Affairs and Emory University, demonstrating that parenteral GDNF, or Glial Cell-Derived Neurotrophic Factor, directly reprograms liver fat metabolism at the genetic level in a preclinical model of metabolic-associated fatty liver disease, or MAFLD. The data highlights statistically significant improvements in key genes responsible for fat production and fat metabolism, positioning GDNF as a potentially differentiated therapeutic approach targeting the root cause of fatty liver disease and metabolic dysfunction. Statistically significant reduction in Srebf1, a key gene driving fat production in the liver: Increased expression of Pparalpha, a central regulator of fat metabolism and fat burning; GDNF outperformed semaglutide in key gene expression markers tied to liver fat regulation; Demonstrated broad metabolic impact at the genetic level, not just weight reduction. Unlike existing therapies that primarily focus on weight loss, GDNF directly targets the biological mechanisms responsible for fat accumulation in the liver. Hoth plans to: Advance HT-VA findings into additional preclinical validation studies; Evaluate clinical development pathways for metabolic and liver diseases; and explore strategic partnerships and collaborations to accelerate development.
